Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the efficacy and safety of a chemotherapy regimen of intravenous Herceptin, cisplatin and gemcitabine in patients with metastatic urothelial cancer. The anticipated time on study treatment is until disease progression.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02006667
Study type Interventional
Source Hoffmann-La Roche
Contact
Status Completed
Phase Phase 2
Start date January 2001
Completion date January 2010

See also
  Status Clinical Trial Phase
Completed NCT02928406 - A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract Phase 3
Recruiting NCT05544552 - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations Phase 1/Phase 2
Recruiting NCT02379429 - Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
Recruiting NCT05038657 - Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC). Phase 2
Completed NCT04430842 - Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Phase 1
Recruiting NCT04718948 - Multimodal Spectroscopy to Detect Urothelial Cancer in Urine
Terminated NCT02013765 - A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer Phase 2
Completed NCT03410641 - Long-term Cancer Risk in the Randomised Oslo Diet and Antismoking Study N/A
Completed NCT03013920 - CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma